Economic Evaluation of Pneumococcal Vaccination in Egypt: Cost-Effectiveness, Budget Impact, and Domestic Manufacturing Potential
PCV introduction in Egypt represents a high-value investment. Immediate introduction maximizes health and economic benefits, while delayed introduction entails substantial opportunity costs. Alternative PCV10-to-PCV13 pathways offer a more affordable route with a similar long-term impact.
Authors
- Chrissy Bishop (ORCID: https://orcid.org/0000-0002-0790-2395)
- A Hagens
- Sowmya Kadandale
- Saadia Farrukh (ORCID: https://orcid.org/0000-0001-8152-0662)
- Ibironke Oyatoye
- Konstantina Politopoulou
- Motuma Abeshu
- Federico Rodriguez-Cairoli
- Zicheng Wang
Institutions
- United Nations Children's Fund (US)
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- TQ Pharma (Jordan) (JO)
Publication Details
- Journal
- Vaccines
- Published
- 2026-04-01
- DOI
- https://doi.org/10.3390/vaccines14040318
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- GAVI Alliance
- UNICEF